GlassScriptPhysician profile
Carmen E Gota
NPI 1568427052
$55,518.06
in general payments reported to CMS, 2019-2025
22 companies · $5,217 in 2025
The $5,217 reported for 2025 was more than what 86% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.21 · 2020: $1,167 · 2022: $900 · 2023: $17K · 2024: $32K · 2025: $5,217.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $41K · Travel and Lodging: $8,500 · Food and Beverage: $3,826 · Education: $163.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $40,950.00 |
| Travel and Lodging | $8,499.52 |
| Food and Beverage | $3,825.70 |
| Education | $163.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $50,657.98 | 2022-2025 | Nucala, Benlysta |
| Jazz Pharmaceuticals INC. | $1,166.67 | 2020 | |
| Amgen INC. | $674.91 | 2022-2024 | Enbrel, Otezla, Tavneos |
| Janssen Biotech, INC. | $589.14 | 2022-2024 | Tremfya, Simponi, Simponi Aria |
| Abbvie INC. | $547.25 | 2022-2024 | |
| Ucb, INC. | $329.77 | 2022-2024 | Cimzia |
| Astrazeneca Pharmaceuticals LP | $267.76 | 2022-2024 | Saphnelo, Evusheld |
| Horizon Therapeutics Plc | $248.49 | 2019-2023 | Krystexxa |
| Genentech USA, INC. | $186.65 | 2022-2023 | Actemra, Rituxan, Ocrevus |
| Novartis Pharmaceuticals Corporation | $169.16 | 2022-2024 | |
| Organon LLC | $152.06 | 2022-2024 | Hadlima, Renflexis |
| Lilly USA, LLC | $127.76 | 2022-2024 | Taltz, Olumiant |
| Vivus LLC | $97.14 | 2023 | Qsymia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $96.64 | 2023-2024 | Cyltezo |
| Ani Pharmaceuticals, INC. | $44.09 | 2023 | Purified Cortrophin Gel |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $31.52 | 2023 | Idacio |
| Pfizer INC. | $30.91 | 2022-2023 | |
| Mallinckrodt Hospital Products INC. | $30.83 | 2022-2023 | Acthar |
| Radius Health, INC. | $20.97 | 2022 | |
| Mylan Institutional INC. | $20.82 | 2023 | Hulio |
| Boston Scientific Corporation | $14.53 | 2025 | General - Pain Management |
| Teva Pharmaceuticals USA, INC. | $13.01 | 2023 | Truxima |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carmen Gota listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.